Cancer Chemotherapy and Biological Response Modifiers Annual 21

Section 1: Drugs. Thymidylate Synthase Inhibitors (S. Ackland).
New Nucleoside Analogues in Clinical Development (W. Plunkett).
Anthracyclines (L. Gianni). Tubulin Targeting Agents (W.H.
Nait). Topoismerase I Interactive Agents (C.F. Stewart).
Topoisomerase II Inhibitors (K. Hande). Farnesyltransferase
Inhibitors (A.A. Adjei). Cyclin-Dependent Kinases as Targets for
Cancer Therapy (A.M. Senderowicz). DNA-Binding Agents (Y.
Nieto). The Evolving Role of Endocrine Therapy for the Treatment
and Prevention of Breast Cancer (W. Gradishar). New Targets for
Cancer Chemotherapy (A.J. Murgo). Section 2: Biological Response
Modifiers. The Graft-versus-Tumor Effect and the Escape of
Maliganancy from Immune Regulation (A.J. Barrett. Donor
Lymphocyte Infusions for Hematopoitic Malignancy (S. Slavin).
Diptheria Toxin Conjugate Therapy of Cancer (A.E. Frankel).
Genetically Engineered T Cells as Adoptive Immunotherapy of
Cancer (R.P. Junghans). Integrating IL-12 into Therapeutic
Cancer Vaccines (T. Grajewski). Immunotherapy for Breast Cancer
(K.L. Knutson). Immunotherapy of Melanoma (P.B. Chapman). CEA
Loaded Dendritic Cell Vaccines (M.A. Morse). Section 3: Tumours.
Leukemias and Plasma Cell Myeloma (P. Wiernik). Lymphomas (A.
Santoro). Head and Neck Cancer (M. Al-Sarraf). Upper
Gastrointestinal Tumors (K. Aiba). Cancers of the Large Bowel
and Hepatobiliary Tract (T.S. d'Entremont). Malignant
Neuroendocrine Tumors (E. Tiensuu). Genitourinary Malignancies
(M.D. Michaelson). Breast Cancer (G. Bonadonna). Melanoma (A.
Schneeberger). Sarcomas (J. Verweij). Brain Tumors (L. Ashby).
Biology and Therapy of Malignant Solid Tumors in Childhood (H.
van den Berg). Supportive Care (M. Markman). Aids-Associated
Malignancies (M.H. Shah). Section 4: Lung Cancer. CT Screening
for Lung Cancer (C. Henschke). Biology of Lung Cancer (A.
Guzdar). Combined Modality of Treatment of Lung Cancer (NSCLC
and SCLC) (T. Le Chevalier). Update on the Systemic Treatment of
Lung Cancer (G. Giaccone). Novel Therapeutics for Advanced Non-
small Cell Lung Cancer (R. Herbst). Novel therapies for the
Treatment of Non-small Cell Lung Cancer (D. Johnson).